Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The human rabies vaccine (MRC-5 cells) is an **inactivated viral vaccine** prepared from the Pitman-Moore strain of rabies virus grown in human diploid MRC-5 fibroblast cells. The Pitman-Moore strain is propagated in these cells, inactivated, and then formulated as a sterile, stable, freeze-dried suspension for intramuscular injection to immunize against rabies. The primary mechanism is induction of a strong, long-lasting humoral immune response by presenting non-replicating rabies virus particles to the immune system, thereby producing protective neutralizing antibodies. The original human diploid cell-based rabies vaccine was developed as a safer alternative to nerve tissue or egg-based vaccines, offering an improved safety and immunogenicity profile. The vaccine is recommended both for **post-exposure prophylaxis (PEP)** and **pre-exposure prophylaxis (PrEP)** against rabies[7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human rabies vaccine (MRC-5 cells).